TOTAL: $22.95M
Year to Date: $432.62M

Company
(Symbol)#*

Partner
(Country)

Amt.
(M)

Triggering
Event

Details (Date)


BioMarin
Pharmaceuticals
Inc.
(BMRN)

Alliant Pharmaceuticals Inc.

$7.5

Milestone payment

Triggered by FDA approval of Orapred ODT, a tablet formulation of prednisolone for asthma and other conditions; another $8M will be paid within one year (6/1)

Cyntellect
Inc.*

Sigma-Aldrich Corp.

$2.2

Milestone payment

The equity purchase milestone payment stemmed from the companies' Cell Xpress service commercialization agreement (6/7)

GTC
Biotherapeutics
Inc.
( GTCB)

LEO Pharma A/S (Denmark)

$1

Milestone payment

Triggered by a recommendation for approval from European regulators for the antithrombin product Atryn (6/14)

Ligand
Pharmaceuticals
Inc.
(LGND)

Wyeth

ND

Milestone payment

Triggered by Wyeth's submission of a new drug application to the FDA for bazedoxifene as a postmenopausal osteoporosis therapy (6/26)

Nastech
Pharmaceutical
Co. Inc.
(NSTK)

Procter & Gamble Pharmaceuticals Inc.

$7

Milestone payment

Nastech attained a development milestone in their deal to develop PTH1-34, a parathyroid hormone nasal spray, for osteoporosis (6/8)

Rigel Pharmaceuticals Inc. (RIGL)

Merck & Co. Inc.

$1

Milestone payment

Triggered by progress in their 2004 collaboration to explore ubiquitin ligases for treating cancer and other diseases (6/13)

Seattle
Genetics Inc.
(SGEN)

CuraGen Corp. (CRGN)

ND

Milestone payment

Triggered by CuraGen's initiation of a Phase I trial of the antibody-drug conjugate agent CR011-vcMMAE for treating metastatic melanoma (6/22)

Sunesis
Pharmaceuticals
Inc.
(SNSS)

Merck & Co. Inc.

$4.25

Milestone payment

Sunesis met certain preclinical milestones in their deal to develop small-molecule inhibitors of beta-amyloid converting enzyme (6/12)


Notes:
# Unless otherwise indicated, shares are traded on the Nasdaq exchange.
* Private company.
Currency conversions are based on exchange rates at the time of the deal.
ND = Not disclosed.

No Comments